Analyzing KalVista Pharmaceuticals (KALV) & Tokai Pharmaceuticals (NVUS)
KalVista Pharmaceuticals (NASDAQ: KALV) and Tokai Pharmaceuticals (NASDAQ:NVUS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
Valuation & Earnings
This table compares KalVista Pharmaceuticals and Tokai Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$625,000.00||174.99||-$16.21 million||N/A||N/A|
|Tokai Pharmaceuticals||N/A||N/A||-$4.10 million||N/A||N/A|
Tokai Pharmaceuticals has higher revenue, but lower earnings than KalVista Pharmaceuticals.
This table compares KalVista Pharmaceuticals and Tokai Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for KalVista Pharmaceuticals and Tokai Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KalVista Pharmaceuticals presently has a consensus target price of $27.00, indicating a potential upside of 139.79%. Given KalVista Pharmaceuticals’ higher possible upside, equities research analysts plainly believe KalVista Pharmaceuticals is more favorable than Tokai Pharmaceuticals.
Insider and Institutional Ownership
75.7% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 39.8% of Tokai Pharmaceuticals shares are held by institutional investors. 49.1% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Tokai Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
KalVista Pharmaceuticals has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, Tokai Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
KalVista Pharmaceuticals beats Tokai Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Tokai Pharmaceuticals Company Profile
Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.